|
1
|
Seki T, Ohshima S, Komatsu S, Yamada S, Kashiwagi H, Goto Y, Tsuda B, Kanno A, Yasuda A, Kuno H, Tsuji NM, Shiina T, Kametani Y. Coccomyxa subellipsoidea KJ Components Enhance the Expression of Metallothioneins and Th17 Cytokines during Human T Cell Activation. Microorganisms 2024; 12:741. [PMID: 38674685 PMCID: PMC11051862 DOI: 10.3390/microorganisms12040741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 03/28/2024] [Accepted: 04/02/2024] [Indexed: 04/28/2024] Open
Abstract
Coccomyxa subellipsoidea KJ (C-KJ) is a green alga with unique immunoregulatory characteristics. Here, we investigated the mechanism underlying the modification of T cell function by C-KJ components. The water-soluble extract of C-KJ was fractionated into protein (P) and sugar (S) fractions acidic (AS), basic (BS), and neutral (NS). These fractions were used for the treatment of peripheral blood mononuclear cells stimulated with toxic shock syndrome toxin-1. Transcriptome analysis revealed that both P and AS enhanced the expression of the genes encoding metallothionein (MT) family proteins, inflammatory factors, and T helper (Th) 17 cytokine and suppressed that of those encoding Th2 cytokines in stimulated T cells. The kinetics of MT1 and MT2A gene expression showed a transient increase in MT1 and maintenance of MT2A mRNA after T cell stimulation in the presence of AS. The kinetics of Th17-related cytokine secretion in the early period were comparable to those of MT2A mRNA. Furthermore, our findings revealed that static, a STAT-3 inhibitor, significantly suppressed MT2A gene expression. These findings suggest that the expression of MTs is involved in the immune regulatory function of C-KJ components, which is partially regulated by Th17 responses, and may help develop innovative immunoregulatory drugs or functional foods.
Collapse
Affiliation(s)
- Toshiro Seki
- Department of Internal Medicine, Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara 259-1193, Japan; (T.S.); (A.Y.)
| | - Shino Ohshima
- Department of Molecular Life Science, Division of Basic Medical Science, Tokai University School of Medicine, Isehara 259-1193, Japan; (S.O.); (T.S.)
| | - Satoko Komatsu
- DENSO CORPORATION, Kariya 448-0029, Japan; (S.K.); (H.K.)
| | - Soga Yamada
- Department of Molecular Life Science, Division of Basic Medical Science, Tokai University School of Medicine, Isehara 259-1193, Japan; (S.O.); (T.S.)
| | - Hirofumi Kashiwagi
- Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara 259-1193, Japan
| | - Yumiko Goto
- Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara 259-1193, Japan
| | - Banri Tsuda
- Department of Palliative Medicine, Tokai University School of Medicine, Isehara 259-1193, Japan
| | - Akiko Kanno
- DENSO CORPORATION, Kariya 448-0029, Japan; (S.K.); (H.K.)
| | - Atsushi Yasuda
- Department of Internal Medicine, Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara 259-1193, Japan; (T.S.); (A.Y.)
| | - Hitoshi Kuno
- DENSO CORPORATION, Kariya 448-0029, Japan; (S.K.); (H.K.)
| | - Noriko M Tsuji
- Division of Immune Homeostasis, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 113-8602, Japan
- Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 113-8602, Japan
- Department of Food Science, Jumonji University, Niiza 352-8510, Japan
| | - Takashi Shiina
- Department of Molecular Life Science, Division of Basic Medical Science, Tokai University School of Medicine, Isehara 259-1193, Japan; (S.O.); (T.S.)
- Institute of Advanced Biosciences, Tokai University, Hiratsuka 259-1207, Japan
| | - Yoshie Kametani
- Department of Molecular Life Science, Division of Basic Medical Science, Tokai University School of Medicine, Isehara 259-1193, Japan; (S.O.); (T.S.)
- Institute of Advanced Biosciences, Tokai University, Hiratsuka 259-1207, Japan
| |
Collapse
|
|
2
|
Therapeutic Effects of a Dry Powder Prepared from the Green Microalga Coccomyxa sp. KJ in Mice Infected with Influenza A Virus. Appl Microbiol 2022. [DOI: 10.3390/applmicrobiol2030037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Influenza virus is a seasonal respiratory pathogen that produces global pandemics by genome reassortments. This rapid evolution creates difficulty in producing vaccines. Although several anti-influenza drugs have been developed, acquisition of rapid drug resistance by viruses is common. Therefore, it is important to develop novel therapeutic and prophylactic strategies. In this study, we evaluated the antiviral effects of a microalgae Coccomyxa sp. KJ (IPOD FERM BP-22254) extract in a BALB/c mouse model of influenza. Oral administration of dry algal powder (5 mg/day or 20 mg/day) before infection with influenza A virus (IFV) suppressed viral proliferation in the lungs and bronchoalveolar lavage fluid (BALF). It also exhibited stimulatory effects on systemic and local production of neutralizing antibodies. These results suggest that this powder is a promising candidate for the therapeutic and prophylactic management of influenza.
Collapse
|